Prehliadač alebo jeho nastavenia nie sú podporované.

Praktik.ai používa moderné webové technológie kvôli bezpečnosti, rýchlosti a spoľahlivému prihlasovaniu. Tento prehliadač ich nepodporuje alebo blokuje JavaScript, preto sa aplikácia nemusí správne načítať.

Aktualizujte prosím Chrome, Edge, Firefox alebo Safari na najnovšiu verziu a stránku potom obnovte.

Ak používate Windows 7, Windows 8 alebo Windows 8.1, Chrome a Edge už nemusia ponúkať novú verziu. V takom prípade použite novšie zariadenie alebo kontaktujte podporu Praktik.ai.

Prohlížeč nebo jeho nastavení nejsou podporované.

Praktik.ai používá moderní webové technologie kvůli bezpečnosti, rychlosti a spolehlivému přihlašování. Tento prohlížeč je nepodporuje nebo blokuje JavaScript, proto se aplikace nemusí správně načíst.

Aktualizujte prosím Chrome, Edge, Firefox nebo Safari na nejnovější verzi a stránku potom obnovte.

Pokud používáte Windows 7, Windows 8 nebo Windows 8.1, Chrome a Edge už nemusí nabízet novou verzi. V takovém případě použijte novější zařízení nebo kontaktujte podporu Praktik.ai.

Your browser or its settings are not supported.

Praktik.ai uses modern web technologies for security, speed, and reliable sign-in. This browser does not support them, or JavaScript is blocked, so the app may not load correctly.

Please update Chrome, Edge, Firefox, or Safari to the latest version and then reload this page.

If you use Windows 7, Windows 8, or Windows 8.1, Chrome and Edge may no longer offer a newer version. In that case, use a newer device or contact Praktik.ai support.

62026TO0363(01)

ORDER OF THE PRESIDENT OF THE GENERAL COURT

16 November 2026 (*)

In Case T‑363/26 R,

Troy Chemical Company BV, established in Delft (Netherlands), represented by A. Dootalieva, M. Grunchard, A. Kila and K. Van Maldegem, lawyers,

applicant,

v

European Chemicals Agency (ECHA), represented by C. Buchanan and N. Knight, acting as Agents,

defendant,

THE PRESIDENT OF THE GENERAL COURT

having regard to the order of 5 August 2026, Troy Chemical Company v ECHA (T‑363/26 R, not published),

makes the following

Order

1 By its application under Articles 278 and 279 TFEU, the applicant, Troy Chemical Company BV, seeks, first, suspension of the operation of the decision of the European Chemicals Agency (ECHA) of 26 March 2026, by which ECHA included Vink Chemicals GmbH & Co. KG as an authorised supplier of the active substance 3-iodo-2-propynylbutylcarbamate (IPBC) for product-type 7 (film preservatives) in the list of active substances and their suppliers provided for in Article 95 of Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ 2012 L 167, p. 1) (‘the contested decision’), and, second, the grant of any other interim measures which the President of the General Court may consider appropriate.

Background to the dispute and forms of order sought by the parties

2 The applicant is a company governed by Dutch law. It is one of four participants in the review programme as regards IPBC for product-type 7 and is included in the list of active substances and their suppliers provided for in Article 95 of Regulation No 528/2012 as an authorised supplier of IPBC for product-type 7.

3 Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (OJ 1998 L 123, p. 1) established a regime under which biocidal active substances were approved, by product-type, at EU level, and biocidal products containing those substances had to be authorised before they were placed on the market; that authorisation was subject, inter alia, to approval of the active substance. A transitional regime, known as the ‘review programme’, was established for ‘existing substances’, that is to say, substances already on the market on 14 May 2000, in accordance with Article 16(2) of Directive 98/8. On 1 September 2013, Regulation No 528/2012 entered into force and repealed that directive. The procedure has nevertheless remained the same and still comprises two stages, namely the approval of an active substance, followed by the authorisation of a biocidal product; that second stage is subject to compliance with several conditions. Article 89 of that regulation provides, moreover, for the continuation of the review programme provided for by Directive 98/8 and for a transitional period allowing existing biocidal products to remain on the market, subject to compliance with Article 95(2) of that regulation and with national legislation.

4 IPBC is a biocidal product. More specifically, it is a fungicide used to prevent mildew growth in coatings prepared from oil-based and water-based paints. It is also used for wood preservation, in metal working fluids and other applications where it is desirable to protect a surface or a liquid composition from the discolouring and destructive effects of fungal growth.

5 As is apparent from recital 1 of Regulation No 528/2012, biocidal products are necessary for the control of organisms that are harmful to human or animal health and for the control of organisms that cause damage to natural or manufactured materials, but can pose risks to humans, animals and the environment due to their intrinsic properties and associated use patterns.

6 Since the entry into force of Regulation No 528/2012, certain tasks concerning the operation of that regulation have been conferred, pursuant to Article 74 of that regulation, on ECHA, established by Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ 2006 L 396, p. 1, corrigendum OJ 2007 L 136, p. 3).

7 Under Regulation No 528/2012, and more specifically Article 95 thereof, ECHA is to be responsible for the establishment of a list containing information on active substances and grouping the suppliers of those substances. In accordance with Article 95(2), from 1 September 2015, a biocidal product consisting of, containing or generating a relevant substance may not be made available on the EU market if the substance supplier or product supplier is not included in the list provided for in that article for the product-type to which that product belongs.

8 The second subparagraph of Article 95(1) of Regulation No 528/2012 provides:

‘A person established within the Union who manufactures or imports a relevant substance, on its own or in biocidal products … or who manufactures or makes available on the market a biocidal product consisting of, containing or generating that relevant substance …, may at any time submit to [ECHA] either a complete substance dossier for that relevant substance, a letter of access to a complete substance dossier, or a reference to a complete substance dossier for which all data protection periods have expired. …’

9 On 16 January 2026, Vink Chemicals submitted to ECHA an application for inclusion in the list provided for in Article 95 of Regulation No 528/2012 as a supplier of IPBC for product-types 6, 7 and 13, referring to the corresponding ‘complete substance dossiers’, as submitted, according to it, in the review programme.

10 In the course of the procedure initiated following that application, ECHA informed Vink Chemicals that inclusion in the list provided for in Article 95 of Regulation No 528/2012 could entail an obligation for it to pay compensation to the owner of the data concerned.

11 On 26 March 2026, ECHA adopted the contested decision.

12 By application lodged at the Registry of the General Court on 9 June 2026, YOU Solutions Germany GmbH and the applicant brought an action seeking the annulment of the contested decision.

13 By separate document lodged at the Court Registry on 3 August 2026, the applicant made the present application for interim measures, in which it claims, in essence, that the President of the General Court should:

– suspend the operation of the contested decision, pending the decision of the General Court on the action in the main proceedings;

– grant any other interim measures as appropriate and hold an oral hearing as needed;

– order ECHA to pay the costs.

14 In its observations on the application for interim measures, which were lodged at the Court Registry on 3 September 2026, ECHA contends that the President of the General Court should:

– dismiss that application;

– order the applicant to pay all the costs and expenses incurred for the purposes of the present proceedings.

Law

General considerations

15 It is apparent from reading Articles 278 and 279 TFEU together with Article 256(1) TFEU that the judge hearing an application for interim measures may, if he or she considers that the circumstances so require, order that the operation of a measure challenged before the General Court be suspended or prescribe any necessary interim measures. Nevertheless, Article 278 TFEU establishes the principle that actions do not have suspensory effect, since acts adopted by the institutions of the European Union are presumed to be lawful. It is therefore only exceptionally that the judge hearing an application for interim measures may order the suspension of operation of an act challenged before the General Court or prescribe any interim measures (see order of 19 July 2016, Belgium v Commission, T‑131/16 R, EU:T:2016:427, paragraph 12 and the case-law cited).

16 The first sentence of Article 156(4) of the Rules of Procedure of the General Court provides that an application for interim measures must state ‘the subject matter of the proceedings, the circumstances giving rise to urgency and the pleas of fact and law establishing a prima facie case for the interim measure applied for’.

17 Thus, the judge hearing an application for interim measures may order suspension of operation of an act and other interim measures, if it is established that such an order is justified, prima facie, in fact and in law, and that it is urgent in so far as, in order to avoid serious and irreparable damage to the interests of the party requesting the interim measures, it must be made and produce its effects before a decision is reached in the main action. Those conditions are cumulative, and consequently an application for interim measures must be dismissed if any one of them is not satisfied. The judge hearing an application for interim measures is also to undertake, when necessary, a weighing of the competing interests (see order of 2 March 2016, Evonik Degussa v Commission, C‑162/15 P-R, EU:C:2016:142, paragraph 21 and the case-law cited).

18 In the context of that overall examination, the judge hearing the application for interim measures enjoys a broad discretion and is free to determine, having regard to the particular circumstances of the case, the manner and order in which those various conditions are to be examined, there being no rule of law imposing a pre‑established scheme of analysis within which the need to order interim measures must be assessed (see order of 19 July 2012, Akhras v Council, C‑110/12 P(R), not published, EU:C:2012:507, paragraph 23 and the case-law cited).

19 As regards the applicant’s request that the President of the General Court organise a hearing if necessary, it should be borne in mind that the judge hearing the application for interim measures alone has jurisdiction to assess the relevance of such a request to the subject matter of the dispute and the need to obtain clarification from the parties in order to rule on the dispute (see order of 20 September 2021, Czech Republic v Poland, C‑121/21 R, EU:C:2021:752, paragraph 13 and the case-law cited).

20 Having regard to the material in the case file, the President of the General Court considers that he has all the information needed to rule on the present application for interim measures without there being any need first to hear oral argument from the parties, with the result that the applicant’s request for a hearing must be refused.

21 In the circumstances of the present case, it is appropriate to examine first of all whether the condition relating to urgency is satisfied.

The condition relating to urgency

22 In order to determine whether the interim measures sought are urgent, it should be noted that the purpose of the procedure for interim relief is to guarantee the full effectiveness of the future final decision, in order to prevent a lacuna in the legal protection afforded by the EU judicature. To attain that objective, urgency must generally be assessed in the light of the need for an interlocutory order to avoid serious and irreparable damage to the party requesting the interim measures. That party must demonstrate that it cannot await the outcome of the main proceedings without suffering serious and irreparable damage (see, to that effect, order of 14 January 2016, AGC Glass Europe and Others v Commission, C‑517/15 P-R, EU:C:2016:21, paragraph 27 and the case-law cited). The condition relating to the seriousness of the damage and the condition relating to its irreparable nature are cumulative conditions (see, to that effect, order of 29 April 2025, Advanz Pharma v Commission, C‑859/24 P(R), not published, EU:C:2025:315, paragraph 66).

23 It is in the light of those criteria that it must be examined whether the applicant has succeeded in demonstrating urgency.

24 In the first place, the applicant submits that, in assessing the serious and irreparable nature of the damage alleged, the judge hearing the application for interim measures should consider the specific circumstances of its situation rather than mechanically apply the legal conditions relating to that assessment.

25 In that regard, the applicant submits, first, that the contested decision was adopted in accelerated fashion in the context of a temporary legal vacuum caused by the delayed publication of the proposal of the European Parliament and of the Council for a regulation amending Regulation No 528/2012 as regards the extension of certain data protection periods. Second, that situation is further aggravated by the fact that, during the transitional period, that is to say, until IPBC is approved for product-type 7, certain key markets in the European Union have only limited market entry requirements in place. Third, the contested decision recreates precisely the free rider issue that the regime under Article 95 of Regulation No 528/2012 was designed to prevent, namely the entry into the EU market of companies not participating in the review programme, which do not bear equivalent data generation and compliance costs, free riding on the investments previously made by the programme participants. Fourth, the damage to the applicant lies not merely in its lost revenue, but also in the irreversible erosion of its exclusionary property rights and its position on the IPBC market. It lies also in the total distortion of rights that the EU legislature intended it to enjoy had the data protection rules applied.

26 ECHA disputes the applicant’s line of argument.

27 In that regard, it should be recalled that Article 95(5) of Regulation No 528/2012 provides that all data protection periods for active substance/product-type combinations listed in Annex II to Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8 (OJ 2007 L 325, p. 3), but for which a decision on inclusion in Annex I to Directive 98/8 was not taken before 1 September 2013, end on 31 December 2025.

28 Recital 7 of Regulation (EU) 2026/1165 of the European Parliament and of the Council of 20 May 2026 amending Regulation No 528/2012 as regards the extension of certain data protection periods (OJ L, 2026/1165) states that, following the expiry of the protection periods on 31 December 2025, the data concerned were unprotected in the period from 1 January 2026 to 15 June 2026. It states also that, during that period, alternative suppliers of the substances concerned and suppliers of the products concerned have been included in the list referred to in Article 95 of Regulation No 528/2012. Since those suppliers could have benefited from the costs incurred by the participants in the examination of those substances and those products to generate such data, that recital states that Article 95(5) was amended to allow data owners to claim compensation from those substance suppliers and product suppliers, if they find it appropriate.

29 Article 1(2) of Regulation 2026/1165 thus amended Regulation No 528/2012 as follows:

‘in Article 95, paragraph 5, the following subparagraphs are added:

“By way of derogation from the first subparagraph of this paragraph, all data protection periods for active substance/product-type combinations for which a decision on the approval has not been adopted in accordance with Article 89(1), third subparagraph, by 7 June 2018, shall end on 31 December 2030.

Data owners may claim compensation for access to their data for the period from 1 January 2026 to 15 June 2026 from a substance supplier or product supplier having benefitted from the absence of protection and having been included in the list referred to in paragraph 1 of this Article during that period.”.’

30 In the present case, the applicant submits that the judge hearing the application for interim measures should take into account the four circumstances specific to its situation referred to in paragraph 25 above in order to assess the serious and irreparable nature of the damage caused to it. It follows from the foregoing that the first three specific circumstances relied on by the applicant appear, prima facie, to result directly from the regulatory framework established by Regulation No 528/2012 and subsequently by Regulation 2026/1165, which the applicant has not sought to challenge. Therefore, those circumstances constitute the legal framework applicable to the present dispute and it is, on that basis, for the judge hearing the application for interim measures to take account of them. However, those circumstances cannot, as such, form part of the assessment of the damage alleged by the applicant. As regards the fourth specific circumstance, which describes in fact the damage that the applicant alleges to have suffered, it will be examined when the existence of that damage is assessed.

31 In the second place, the applicant claims that, if the interim measures sought are not granted, it will suffer serious and irreparable legal damage. According to the applicant, such damage takes two forms. First, it would cause the loss of its exclusive right to refuse the sharing of data that are not subject to mandatory data sharing under Article 95(3) of Regulation No 528/2012, in particular data on physical and chemical properties of IPBC, on analytical methods and on efficacy, namely the loss of its right to property under Article 17 of the Charter of Fundamental Rights of the European Union (‘the Charter’). Second, it would result, for the applicant, in the loss of the effective benefit of the data-sharing mechanism under Articles 62 and 63 of that regulation.

32 In that regard, the applicant states that it does not claim that the damage linked to its right to property under Article 17 of the Charter is, by definition, irreparable merely because it falls within the scope of fundamental rights.

33 By contrast, the applicant submits that it satisfies the conditions laid down by the case-law according to which the assessment of whether serious and irreparable damage exists depends on a combination of factors, including, inter alia, the commercial significance of the data concerned for the undertaking that provided them and their usefulness to other market participants.

34 ECHA disputes the applicant’s line of argument.

35 In that regard, it must be noted that, according to the case-law, the assessment of whether serious and irreparable damage would be caused to the party requesting the adoption of interim measures in order to prevent access to data which are not subject to mandatory data sharing under Article 95(3) of Regulation No 528/2012, or to retain the effective benefit of the data-sharing mechanism provided for in Articles 62 and 63 of that regulation, depends on a combination of factors, such as, inter alia, how significant the data concerned are in commercial terms for the undertaking which provided those data and the usefulness of those data for other market participants (see order of 14 September 2026, SNF Group v ECHA, T‑244/26 R, not published, EU:T:2026:560, paragraph 34 and the case-law cited).

36 In the present case, first, the applicant submits that the significance in commercial terms of the data concerned is indisputable on account of the magnitude of the sums which it invested to generate both its own data and the data held jointly with the other members of the IPBC Task Force. Second, it submits that the data relating to physicochemical properties, analytical methods and efficacy are of considerable value for other suppliers, such as Vink Chemicals, since, under Article 95(1) and (5) of Regulation No 528/2012, those companies are required to refer to a complete dossier. The applicant adds that the context of the use of its data provides useful insights on the significance of those data to itself, Vink Chemicals and other suppliers listed on the basis of Article 95(5) of Regulation No 528/2012.

37 In that regard, first of all, it should be borne in mind that Article 63(1) of Regulation No 528/2012 provides that, where a request for data sharing has been made in accordance with Article 62(2) of that regulation, the prospective applicant and the data owner are to make every effort to reach an agreement on the sharing of the results of the tests or studies requested by the prospective applicant. Article 63(3) of that regulation provides that, where no agreement is reached with respect to data involving tests or studies on vertebrates, ECHA is to give the prospective applicant permission, within 60 days of being informed, to refer to the requested tests or studies on vertebrates, provided that the prospective applicant demonstrates that every effort has been made to reach an agreement and that the prospective applicant has paid the data owner a share of the costs incurred. That provision states also that, where the prospective applicant and data owner cannot agree, national courts are to decide on the proportionate share of the cost that the prospective applicant is to pay to the data owner. Lastly, pursuant to that provision, the data owner is not to refuse to accept any payment offered under the second subparagraph of Article 63(3), any acceptance being, however, without prejudice to the right of that owner to have the proportionate share of the cost determined by a national court, in accordance with the second subparagraph of Article 63(3).

38 Next, it follows from the second subparagraph of Article 95(1) of Regulation No 528/2012 that a person established in the European Union who manufactures or imports a relevant substance, on its own or in biocidal products, or who manufactures or makes available on the market a biocidal product consisting of, containing or generating the relevant substance, may at any time submit to ECHA either a complete dossier for that relevant substance, a letter of access to a complete substance dossier, or a reference to a complete substance dossier for which all data protection periods have expired.

39 Lastly, in accordance with Article 95(3) of Regulation No 528/2012, for the purposes of making a submission of an application in accordance with the second subparagraph of Article 95(1), Article 63(3) of that regulation is to apply to all toxicological, ecotoxicological and environmental fate and behaviour studies relating to substances listed in Annex II to Regulation No 1451/2007, including any such studies not involving tests on vertebrates.

40 In the present case, Vink Chemicals was able to refer to a complete IPBC dossier for the purposes of its inclusion in the list provided for in Article 95 of Regulation No 528/2012. However, that ability was, prima facie, made possible by Article 95(5) of that regulation, which set 31 December 2025 as the date on which the protection of data relating to that substance ended. Thus, at the date of the adoption of the contested decision, no protection of the data at issue applied to complete IPBC dossiers. In those circumstances, as ECHA correctly states, it appears, prima facie, first, that Vink Chemicals could, under the second subparagraph of Article 95(1) of Regulation No 528/2012, refer to a complete IBPC dossier for which all data protection periods had expired and, second, that the applicant was no longer in a position to rely on the data-sharing compensation mechanism provided for in Article 63 of Regulation No 528/2012.

41 It follows from the foregoing that, prima facie, it was the end of the protection of the data at issue provided for in Article 95 of Regulation No 528/2012 that enabled ECHA to include Vink Chemicals in the list provided for in that article. Therefore, the applicant cannot validly claim, in the present proceedings, that the contested decision deprives it of the legal rights arising from that regulation. The applicant has therefore failed to establish, in its application for interim measures, that the contested decision would cause it serious and irreparable legal damage.

42 Moreover, even assuming that, while arguing that there is legal damage, the applicant was in fact seeking to rely on financial damage, it must be borne in mind that, following the entry into force of Regulation 2026/1165, Article 95(5) was amended to allow data owners to claim compensation from the suppliers of the substances concerned and from the suppliers of the products concerned, if they find it appropriate. Thus, that regulation amended Article 95(5) of Regulation No 528/2012 by providing for the possibility for data owners to claim compensation for access to their data for the period from 1 January 2026 to 15 June 2026 from a substance supplier or a product supplier where that supplier benefited from the absence of protection and was included in the list referred to in Article 95(1) of Regulation No 528/2012 during that period. Therefore, that damage alleged by the applicant cannot be classified as either serious or irreparable within the meaning of the case-law cited in paragraph 22 above.

43 In the third place, the applicant submits that it will suffer significant financial and commercial damage, first, owing to the loss of its position on the EU IPBC market to Vink Chemicals, second, as a result of the aggravation of its losses because of the macroeconomic context, that is to say, in particular, the exceptional geopolitical tensions in the Middle East, and, third, on account of being compelled to withdraw from the review programme because of its financial and commercial losses and the resulting pressure on its profit margins.

44 ECHA disputes the applicant’s line of argument.

45 In that regard, according to settled case-law, where the damage referred to is of a financial nature, the interim measures sought are justified where, in the absence of those measures, the applicant would be in a position that would imperil its financial viability before final judgment is given in the main action, or where its market share would be affected substantially in the light, inter alia, of the size and turnover of its undertaking and the characteristics of the group to which it belongs (see order of 25 February 2025, WebGroup Czech Republic v Commission, C‑620/24 P(R), EU:C:2025:136, paragraph 17 and the case-law cited).

46 While account can also be taken of the fact that, if the interim measure sought were not granted, the applicant’s market share would be irremediably affected, it must be pointed out that that situation can be placed on an equal footing with that of the risk of disappearance from the market and justify adoption of the interim measure sought only if the irremediable effect on market share is also of a serious nature. It is therefore not sufficient that a market share may be irremediably lost by an undertaking; rather, it is necessary for that market share to be sufficiently large in the light of, in particular, the size of that undertaking, regard being had to the characteristics of the group to which it belongs through its shareholders. An applicant who invokes the loss of such a market share must demonstrate, furthermore, that regaining a significant proportion of that share is impossible by reason of obstacles of a structural or legal nature (see order of 28 April 2009, United Phosphorus v Commission, T‑95/09 R, not published, EU:T:2009:124, paragraph 35 and the case-law cited).

47 To that end, the judge hearing the application for interim measures must have specific and precise information, supported by detailed, certified documentary evidence, which shows the situation in which the party requesting the adoption of the interim measures finds itself and enables the probable consequences, should the requested measures not be granted, to be assessed (see order of 5 May 2021, Ovsyannikov v Council, T‑714/20 R, not published, EU:T:2021:243, paragraph 32 and the case-law cited).

48 First, the applicant submits that IPBC is the foundation of the applicant’s dry-film preservation business and that that substance underpins a substantial proportion of its broader paints and coatings activities. However, the applicant has not submitted any information capable of establishing the loss of its position on the IPBC market in the European Union. While it states, without, however, substantiating it, that approximately 83% of dry-film products sold by it in Europe contain IPBC, while dry-film preservation accounts for approximately 52% of its European decorative coatings business, it does not specify what its market share is. Furthermore, no specific information is provided in the application for interim measures capable of establishing that, if the interim measure sought were not granted, the applicant’s market share would be irremediably affected. In particular, the applicant has failed to establish that its market share is sufficiently large in the light, in particular, of its size, within the meaning of the case-law cited in paragraph 46 above. The evidence which the applicant has produced is either irrelevant or incomplete and unverifiable, in so far as it refers to uncertified financial data of unknown origin.

49 Second, the applicant has also failed to substantiate its assertions relating to the alleged increase in IPBC’s production costs and the alleged contraction in the market caused by competition from products that are alternatives to IPBC, in respect of which it has merely produced a graph and a table containing data whose source is unknown.

50 Third, as regards the assertion relating to the structure of customer relationships, according to which sales are not secured through guaranteed purchasing commitments but depend on continuous competition, including on price, it must be stated that, in support of that assertion, the applicant has produced only one agreement concluded with a single undertaking, which terminated on 31 December 2020. As ECHA correctly submits, such a factor is not sufficient to establish that that type of agreement was still the norm on the date of the adoption of the contested decision, that is to say, more than five years later.

51 Fourth, the applicant adds that the commercial pressure which will arise from the inclusion of Vink Chemicals in the list provided for in Article 95 of Regulation No 528/2012 would likely lead to a price reduction of at least 20% and is likely to affect not only diverted sales but also its broader customer base. It adds that the cumulative impact of the listing of Vink Chemicals and that of another undertaking is expected to amount for it to a significant annual sales loss and will likely necessitate broader restructuring measures affecting its European operations.

52 In that regard, it must be stated that the applicant has not adduced any evidence in support of those assertions. Therefore, the applicant has not established either the seriousness or the irreparable nature of the damage on which it relies. The same is true of the risk of reputational damage to the applicant, which is not substantiated by any item of evidence.

53 Fifth, the applicant relies on the case-law resulting from the order of 7 March 2013, EDF v Commission (C‑551/12 P(R), EU:C:2013:157, paragraphs 32 and 33), according to which financial damage which is objectively considerable, or even not insignificant, may be regarded as serious, without it being necessary in every case to relate that damage to the turnover of the undertaking which fears suffering it and, therefore, the fact that an applicant has not provided, in its application for interim measures, information concerning the size of the undertaking to which it belongs is not in itself sufficient to justify the dismissal of that application on the ground that the applicant has failed to establish the seriousness of the alleged damage.

54 The applicant adds that, according to the case-law resulting from the order of 11 April 2001, Commission v Cambridge Healthcare Supplies (C‑471/00 P(R), EU:C:2001:218, paragraph 114), in the evaluation of the seriousness of financial damage, the judge hearing the application for interim measures cannot confine himself or herself to having recourse, in a mechanical manner, solely to the relevant turnover or market shares, but must also examine the circumstances of each case.

55 Relying on the case-law referred to in paragraphs 53 and 54 above, the applicant states that it experienced significant supply chain disruptions as a result of tensions in the Middle East. It adds that since global production of IPBC remains principally concentrated outside the European Union, any disruption between the European Union, on the one hand, and Mexico, China and the United States of America, on the other, would further increase costs and constrain availability of that product, further exacerbating the financial damage resulting from intensified competition in the EU market.

56 Nevertheless, it follows from the foregoing that the applicant has again failed to adduce any prima facie evidence in support of its assertions. It cannot rely solely on the exceptional geopolitical circumstances to which it refers in order to establish the seriousness and irreparable nature of the damage alleged by it.

57 Sixth, the applicant states that it is one of the participants in the IPBC review programme for product-type 7 and that, as such, it invested very large sums in generating data and ultimately allowing IPBC to be approved for product-type 7. The applicant states that it would be compelled to withdraw from that programme if Vink Chemicals competed significantly with it on prices, leading to a drop in its sales and, therefore, in its turnover.

58 On that matter, it must be noted that the applicant has not adduced any evidence capable of establishing that it would be compelled to withdraw from the IPBC examination procedure on account of the presence of competitors on the EU market. It has therefore failed to establish the seriousness and irreparable nature of the damage on which it relies. Furthermore, as ECHA correctly submits, a withdrawal from the review programme would not follow from the contested decision, but would result from the choice made by the applicant itself. In any event, even assuming that the applicant would in fact withdraw from the review programme, it would remain the owner of the data at issue and could recover part of its investment by seeking compensation and by selling letters of access to its data, as now provided for in Regulation No 528/2012, as amended by Regulation 2026/1165.

59 In the light of the foregoing, it must be concluded that the applicant has not succeeded in establishing either the seriousness or the irreparable nature of the financial and commercial damage alleged.

60 The application for interim measures must therefore be dismissed in its entirety, since the applicant has failed to establish urgency, without it being necessary to rule on whether there is a prima facie case or to weigh up the interests.

The evidence produced by the applicant and its application for a measure of organisation of procedure

61 By separate document, the applicant submitted new evidence pursuant to Article 85 of the Rules of Procedure and requested that, on the basis of that new evidence, the President of the General Court adopt a measure of organisation of procedure inviting ECHA, in essence, to specify the circumstances under which it decides that suppliers of the substances and products concerned may remain on the list provided for in Article 95 of Regulation No 528/2012.

62 ECHA submitted its observations.

63 Without it being necessary to rule on the admissibility of that new evidence, the President of the General Court considers that there is no need to grant the applicant’s application for a measure of organisation of procedure, since that application is of no relevance to the outcome of the present proceedings. Accordingly, that application is rejected.

64 Pursuant to Article 158(5) of the Rules of Procedure, the costs must be reserved.

On those grounds,

THE PRESIDENT OF THE GENERAL COURT

hereby orders:

1. The application for interim measures is dismissed.

2. The costs are reserved.

Luxembourg, 16 November 2026.

T. Henze

S. Papasavvas

Acting Registrar

President

* Language of the case: English.